Table of Contents
- Trial overview
- Who can join these studies
- Study phases and what they mean
- What the trials measure
- Main cancer areas studied
- Special study types and research questions
- Simple explanation of key trial terms
Trial overview
These clinical trials study Atezolizumab in many different cancer settings, often with other treatments such as chemotherapy, bevacizumab, tiragolumab, radiation, or surgery.[1] The studies look at both how well treatment works and how safe it is in real patient groups.[2] Many trials are in advanced cancer, but some are in earlier stages or after surgery.[3]
Several trials compare Atezolizumab with placebo, standard treatment, or another immunotherapy.[4][5] Other trials test Atezolizumab as part of a combination plan, such as with chemotherapy, targeted therapy, or radiation.[6]
Who can join these studies
The target population changes from trial to trial.[7] Some studies include adults with advanced or metastatic cancer, while others focus on people with resectable disease, meaning the tumor can be removed by surgery.[1] Some trials also focus on special groups, such as patients after chemotherapy and radiotherapy, patients after cystectomy, or patients with high-risk disease after surgery.[4]
There are also studies for specific groups such as pediatric and adult patients with soft tissue sarcoma, elderly patients with non-small cell lung cancer, and patients with liver transplant and recurrent hepatocellular carcinoma.[7][8] Some trials use biomarker selection, which means the study looks for a tumor feature or blood marker before deciding who can join.[9]
Study phases and what they mean
The trial data includes Phase 1, Phase 2, Phase 3, and a few combined phases such as Phase 1/2 or Phase 2/3.[1] Phase 1 studies usually focus on safety, dose, and the first signs of effect.[10] Phase 2 studies usually look at early effectiveness and sometimes safety in a smaller group.[2] Phase 3 studies are larger and often compare Atezolizumab with another treatment, placebo, or standard care.[4]
Some trials also include extension or rollover studies, which are designed to let eligible patients continue treatment after a parent study ends.[11] These studies are not mainly about finding a new effect; they are about continued access and follow-up.[12]
What the trials measure
Many trials use survival outcomes such as overall survival, progression-free survival, disease-free survival, and recurrence-free survival.[1] These measures show whether people live longer, whether the cancer stays controlled, or whether it comes back after treatment.[13]
Other common endpoints are objective response rate, pathological complete response, and major pathological response.[14] These tell researchers how much the tumor shrinks or how much cancer remains in tissue after treatment or surgery.[15] Safety is also a major endpoint in many studies, especially in early-phase trials and combination studies.[2]
Main cancer areas studied
Lung cancer is one of the most common areas studied, including non-small cell lung cancer and small cell lung cancer, in both newly diagnosed and previously treated patients.[16] Several studies test Atezolizumab with chemotherapy, tiragolumab, bevacizumab, radiation, or maintenance treatment after induction therapy.[17]
Liver cancer, especially hepatocellular carcinoma, is another major focus.[18] Trials include first-line treatment, neoadjuvant and adjuvant treatment, post-surgery treatment, and studies in unresectable disease or in patients at high risk of recurrence.[3]
Breast cancer trials include triple-negative breast cancer, HER2-positive breast cancer, and metastatic breast cancer.[2] Some studies examine Atezolizumab with chemotherapy, while others test it with targeted or immune-based combinations.[19]
Other important areas include bladder cancer, mesothelioma, colorectal cancer, lymphoma, melanoma, head and neck cancer, sarcoma, prostate cancer, and cervical cancer.[4] In several of these studies, Atezolizumab is tested after surgery, after chemoradiotherapy, or in patients whose disease has come back or spread.[14]
Special study types and research questions
Some trials are designed to test a new combination, such as Atezolizumab with another immune treatment, chemotherapy, or radiotherapy.[5] Others compare Atezolizumab against standard treatment, placebo, or active surveillance to see which option gives better results.[4]
A few studies are not focused mainly on treatment effect in the usual way. For example, some trials look at imaging with labeled Atezolizumab, skin testing for allergy workups, or blood markers linked to immune toxicity.[20] These studies help researchers learn more about how to select patients, monitor response, or understand treatment reactions.[21]
Simple explanation of key trial terms
Adjuvant treatment means treatment given after the main treatment, often after surgery, to lower the risk that cancer returns.[13] Neoadjuvant treatment means treatment given before surgery to shrink the tumor or improve the chance of a good surgical result.[1]
Maintenance treatment means treatment that continues after the first treatment phase to help keep the disease under control.[14] Randomized means people are assigned by chance to different study groups, so the groups can be compared fairly.[4] Open-label means the treatment assignment is known in the study.[22]
Biomarker-driven means the trial uses a tumor feature, blood feature, or genetic result to guide treatment choice.[23] Histology means the type of cancer cells seen under a microscope, and RECIST is a standard way to measure tumor response on scans.[14]
